Report cover image

North America Gaucher Disease Treatment Market Size, Share, Trends, & Industry Analysis Report: By Type (Type 1, Type 3, Type 2), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034

Publisher Polaris Market Research & Consulting LLP
Published May 01, 2025
Length 129 Pages
SKU # PLRS20199120

Description

The north america gaucher disease treatment market size is expected to reach USD 1,115.87 million by 2034, according to a new study by Polaris Market Research. The report “North America Gaucher Disease Treatment Market Size, Share, Trends, Industry Analysis Report: By Type (Type 1, Type 3, and Type 2), By Therapy, By Distribution Channel, and By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gaucher disease is a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase, leading to the accumulation of glucocerebroside in cells, particularly in the spleen, liver, bone marrow, and sometimes the brain.

North America is home to many of the world’s major biotechnology and pharmaceutical companies involved in Gaucher disease treatment. Companies such as Sanofi, Pfizer, and Takeda have a strong presence in the region and continue to invest heavily in research, development, and marketing. Their efforts have resulted in a steady pipeline of innovative drugs, improved access to therapies, and widespread patient support programs. These industry leaders further form partnerships with academic institutions and healthcare providers to advance treatment options. Their strong market presence is fueling Gaucher disease to remain a priority, driving the market growth in the region.

Personalized medicine, which tailors treatment to an individual’s genetic makeup, is revolutionizing healthcare. In the context of Gaucher disease, personalized approaches help determine the best treatment based on disease severity, patient genetics, and response to therapy. This ensures better outcomes and minimizes unnecessary side effects. Pharmaceutical companies are developing more targeted therapies and diagnostics that align with this trend. Personalized medicine is driving demand for sophisticated and effective Gaucher disease treatments as it becomes more common in North America, thereby driving the market growth.

North America Gaucher Disease Treatment Market Report Highlights

Based on type, the type 1 segment dominated with the largest market share, and was valued at USD 718.40 million in 2024, as type 1 Gaucher disease is the most common form found in North America.

The enzyme replacement therapy segment, by therapy, accounted for a 74.18% share in 2024 as ERT is widely used for treating Gaucher disease, especially for Type 1 patients.

The US Gaucher disease treatment market accounted for 66.28% market share in 2024, driven by advanced healthcare infrastructure, strong research activity, and widespread awareness of rare genetic disorders.

The Canada Gaucher disease treatment market is expected to reach USD 175.30 million by 2034 due to improved diagnosis, patient registries, and universal healthcare coverage.

A few global key market players are Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Eli Lilly and Company; Johnson & Johnson, Inc.; Lingyi Biotechnology; Protalix Biotherapeutics Inc.; Sanofi; Spur Therapeutics; and Takeda Pharmaceutical.

Polaris Market Research has segmented the North America Gaucher disease treatment market report on the basis of type, therapy, distribution channel, and country:

By Type (Revenue – USD Million, 2020–2034)

Type 1

Type 3

Type 2

By Therapy (Revenue – USD Million, 2020–2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel (Revenue – USD Million, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country Outlook (Revenue – USD Million, 2020–2034)

US

Canada

Table of Contents

129 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. North America Fabry’s Disease Treatment Market Insights
4.1. North America Fabry’s Disease Treatment Market – Market Snapshot
4.2. North America Fabry’s Disease Treatment Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. High Diagnostic Rates
4.2.1.2. Technological Advancements in Patient Monitoring
4.2.2. Restraints and Challenges
4.2.2.1. Lack of Awareness
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. North America Fabry’s Disease Treatment Market Trends
4.6. Value Chain Analysis
5. North America Fabry’s Disease Treatment Market, by Route of Administration
5.1. Key Findings
5.2. Introduction
5.2.1. North America Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
5.3. Intravenous Route
5.3.1. North America Fabry’s Disease Treatment Market, by Intravenous Route, by Country, 2020-2034 (USD Million)
5.4. Oral Route
5.4.1. North America Fabry’s Disease Treatment Market, by Oral Route, by Country, 2020-2034 (USD Million)
6. North America Fabry’s Disease Treatment Market, by Therapy
6.1. Key Findings
6.2. Introduction
6.2.1. North America Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
6.3. Enzyme Replacement Therapy (ERT)
6.3.1. North America Fabry’s Disease Treatment Market, by Enzyme Replacement Therapy (ERT), by Country, 2020-2034 (USD Million)
6.4. Substrate Reduction Therapy (SRT)
6.4.1. North America Fabry’s Disease Treatment Market, by Substrate Reduction Therapy (SRT), by Country, 2020-2034 (USD Million)
6.5. Others
6.5.1. North America Fabry’s Disease Treatment Market, by Others, by Country, 2020-2034 (USD Million)
7. North America Fabry’s Disease Treatment Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. North America Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
7.3. Hospital Pharmacies
7.3.1. North America Fabry’s Disease Treatment Market, by Hospital Pharmacies, by Country, 2020-2034 (USD Million)
7.4. Retail Pharmacies
7.4.1. North America Fabry’s Disease Treatment Market, by Retail Pharmacies, by Country, 2020-2034 (USD Million)
7.5. Online Pharmacies
7.5.1. North America Fabry’s Disease Treatment Market, by Online Pharmacies, by Country, 2020-2034 (USD Million)
8. North America Fabry’s Disease Treatment Market, by Geography
8.1. Key Findings
8.2. Introduction
8.2.1. North America Fabry’s Disease Treatment Market Assessment, By Geography, 2020-2034 (USD Million)
8.3. North America Fabry’s Disease Treatment Market – North America
8.3.1. North America: North America Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.2. North America: North America Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.3. North America: North America Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.4. North America Fabry’s Disease Treatment Market – U.S.
8.3.4.1. U.S.: North America Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.4.2. U.S.: North America Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.4.3. U.S.: North America Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.5. North America Fabry’s Disease Treatment Market – Canada
8.3.5.1. Canada: North America Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.5.2. Canada: North America Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.5.3. Canada: North America Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Amicus Therapeutics, Inc.
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. CANbridge Life Sciences Ltd.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Chiesi Farmaceutici S.p.A.
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Idorsia Pharmaceuticals Ltd.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. ISU ABXIS Co., Ltd.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. JCR Pharmaceuticals Co., Ltd.
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Protalix Biotherapeutics Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Sangamo Therapeutics, Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Sanofi
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Takeda Pharmaceutical
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us